• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Eudragit包衣的壳聚糖-泼尼松龙缀合物微球在三硝基苯磺酸诱导的大鼠结肠炎模型中的胃肠道分布及吸收行为

Gastrointestinal distribution and absorption behavior of Eudragit-coated chitosan-prednisolone conjugate microspheres in rats with TNBS-induced colitis.

作者信息

Oosegi Tomoko, Onishi Hiraku, Machida Yoshiharu

机构信息

Department of Drug Delivery Research, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan.

出版信息

Int J Pharm. 2008 Feb 4;348(1-2):80-8. doi: 10.1016/j.ijpharm.2007.07.007. Epub 2007 Jul 13.

DOI:10.1016/j.ijpharm.2007.07.007
PMID:17714892
Abstract

Conjugate of chitosan and succinyl-prednisolone, termed Ch-SP, was synthesized, and Ch-SP microspheres (Ch-SP-MS) and Eudragit L100-coated Ch-SP-MS (Ch-SP-MS/EuL) were prepared using Ch-SP. Ch-SP-MS and Ch-SP-MS/EuL had a mean size of 1.5 and 26.6microm, respectively, and a drug content of 4.6 and 3% (w/w), respectively. Prednisolone (PD) was released very slow in JP 14 first fluid (pH 1.2), and gradually in JP 14 second fluid (pH 6.8). The addition of cecal or colonic content did not accelerate the release. Rats with 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis were used in animal studies. Gastrointestinal distribution and plasma concentration were investigated by oral administration of PD alone and Ch-SP-MS/EuL. For PD alone, PD was distributed at the stomach and small intestine, and disappeared from the gastrointestinal tracts within 8h. When administering Ch-SP-MS/EuL, the drug was distributed mainly in the lower intestine between 3 and 24h. Plasma concentration was much lower in Ch-SP-MS/EuL than in PD alone, suggesting lower toxic side effects of Ch-SP-MS/EuL. Thus, Ch-SP-MS/EuL delivered PD specifically near the diseased site and PD was released gradually, with much less plasma concentration of PD. Ch-SP-MS/EuL are suggested as a useful delivery system to the site of inflammatory bowel disease.

摘要

合成了壳聚糖与琥珀酰泼尼松龙的缀合物,称为Ch-SP,并使用Ch-SP制备了Ch-SP微球(Ch-SP-MS)和Eudragit L100包衣的Ch-SP-MS(Ch-SP-MS/EuL)。Ch-SP-MS和Ch-SP-MS/EuL的平均粒径分别为1.5和26.6微米,药物含量分别为4.6%和3%(w/w)。泼尼松龙(PD)在日本药局方14号第一液(pH 1.2)中释放非常缓慢,在日本药局方14号第二液(pH 6.8)中逐渐释放。添加盲肠或结肠内容物并未加速释放。在动物研究中使用了2,4,6-三硝基苯磺酸(TNBS)诱导结肠炎的大鼠。通过口服单独的PD和Ch-SP-MS/EuL来研究胃肠道分布和血浆浓度。对于单独的PD,PD分布在胃和小肠,并在8小时内从胃肠道消失。当给予Ch-SP-MS/EuL时,药物在3至24小时主要分布在小肠下部。Ch-SP-MS/EuL的血浆浓度远低于单独的PD,表明Ch-SP-MS/EuL的毒副作用较低。因此,Ch-SP-MS/EuL在病变部位附近特异性递送PD,且PD逐渐释放,同时PD的血浆浓度低得多。Ch-SP-MS/EuL被认为是一种用于炎症性肠病部位的有用递送系统。

相似文献

1
Gastrointestinal distribution and absorption behavior of Eudragit-coated chitosan-prednisolone conjugate microspheres in rats with TNBS-induced colitis.Eudragit包衣的壳聚糖-泼尼松龙缀合物微球在三硝基苯磺酸诱导的大鼠结肠炎模型中的胃肠道分布及吸收行为
Int J Pharm. 2008 Feb 4;348(1-2):80-8. doi: 10.1016/j.ijpharm.2007.07.007. Epub 2007 Jul 13.
2
Efficacy and toxicity of Eudragit-coated chitosan-succinyl-prednisolone conjugate microspheres using rats with 2,4,6-trinitrobenzenesulfonic acid-induced colitis.使用2,4,6-三硝基苯磺酸诱导的结肠炎大鼠模型对Eudragit包衣的壳聚糖-琥珀酰-泼尼松龙共轭微球的疗效和毒性研究
Int J Pharm. 2008 Jun 24;358(1-2):296-302. doi: 10.1016/j.ijpharm.2008.02.015. Epub 2008 Mar 10.
3
Novel preparation of enteric-coated chitosan-prednisolone conjugate microspheres and in vitro evaluation of their potential as a colonic delivery system.肠溶壳聚糖-泼尼松龙共轭微球的新型制备及其作为结肠给药系统潜力的体外评价
Eur J Pharm Biopharm. 2008 Feb;68(2):260-6. doi: 10.1016/j.ejpb.2007.06.016. Epub 2007 Jul 4.
4
Eudragit coating of chitosan-prednisolone conjugate microspheres and in vitro evaluation of coated microspheres.壳聚糖-泼尼松龙共轭微球的Eudragit包衣及包衣微球的体外评价
Drug Dev Ind Pharm. 2007 Aug;33(8):848-54. doi: 10.1080/03639040701377904.
5
Kinetic analysis of in vitro and in vivo release of prednisolone from the conjugate of glycol-chitosan and succinyl-prednisolone.甘醇壳聚糖-琥珀酰泼尼松龙接合物在体内外释放泼尼松龙的动力学分析。
Int J Pharm. 2011 May 30;410(1-2):17-22. doi: 10.1016/j.ijpharm.2011.03.004. Epub 2011 Mar 22.
6
Comparison of Simple Eudragit Microparticles Loaded with Prednisolone and Eudragit-Coated Chitosan-Succinyl-Prednisolone Conjugate Microparticles: Part II. In Vivo Evaluation of Efficacy, Toxicity, and Biodisposition Characteristics.载有泼尼松龙的简单Eudragit微粒与Eudragit包衣的壳聚糖-琥珀酰-泼尼松龙共轭微粒的比较:第二部分。功效、毒性和生物处置特性的体内评估。
Int J Mol Sci. 2015 Nov 2;16(11):26125-36. doi: 10.3390/ijms161125949.
7
Comparison of simple Eudragit microparticles loaded with prednisolone and Eudragit-coated chitosan-succinyl-prednisolone conjugate microparticles: Part I. Particle characteristics and in vitro evaluation as a colonic delivery system.载有泼尼松龙的简单Eudragit微粒与Eudragit包衣的壳聚糖-琥珀酰-泼尼松龙共轭微粒的比较:第一部分。作为结肠给药系统的颗粒特性和体外评价。
Drug Dev Ind Pharm. 2012 Jul;38(7):800-7. doi: 10.3109/03639045.2011.628677. Epub 2011 Nov 11.
8
Studies of chitosan/organic acid/Eudragit RS/RL-coated system for colonic delivery.用于结肠给药的壳聚糖/有机酸/聚丙烯酸树脂RS/RL包衣系统的研究
Int J Pharm. 2009 Jan 21;366(1-2):140-8. doi: 10.1016/j.ijpharm.2008.09.006. Epub 2008 Sep 13.
9
Eudragit-coated chitosan-tripterygium glycoside conjugate microspheres alleviate DSS-induced experimental colitis by inhibiting the TLR4/NF-κB signaling pathway.壳聚糖-雷公藤多苷接枝共聚微球包衣减轻 DSS 诱导的实验性结肠炎通过抑制 TLR4/NF-κB 信号通路。
Biomed Pharmacother. 2023 Feb;158:114194. doi: 10.1016/j.biopha.2022.114194. Epub 2023 Jan 3.
10
Preparation and in vitro evaluation of mucoadhesive properties of alginate/chitosan microparticles containing prednisolone.含泼尼松龙的藻酸盐/壳聚糖微粒的制备及其黏膜黏附性能的体外评价
Int J Pharm. 2006 Apr 7;312(1-2):113-8. doi: 10.1016/j.ijpharm.2006.01.003. Epub 2006 Feb 21.

引用本文的文献

1
Impact of Microdevice Geometry on Transit and Retention in the Murine Gastrointestinal Tract.微器件几何形状对肠道转运和滞留的影响。
ACS Biomater Sci Eng. 2023 Jun 12;9(6):2891-2901. doi: 10.1021/acsbiomaterials.0c01606. Epub 2021 Apr 29.
2
Nanogels of a Succinylated Glycol Chitosan-Succinyl Prednisolone Conjugate: Release Behavior, Gastrointestinal Distribution, and Systemic Absorption.琥珀酰化壳聚糖琥珀酸泼尼松龙接枝物的纳米凝胶:释放行为、胃肠道分布和全身吸收。
Int J Mol Sci. 2020 Mar 30;21(7):2376. doi: 10.3390/ijms21072376.
3
Nanogels of Succinylated Glycol Chitosan-Succinyl Prednisolone Conjugate: Preparation, In Vitro Characteristics and Therapeutic Potential.
琥珀酰化壳聚糖-琥珀酰泼尼松龙共轭物纳米凝胶:制备、体外特性及治疗潜力
Pharmaceutics. 2019 Jul 13;11(7):333. doi: 10.3390/pharmaceutics11070333.
4
Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review.微粒作为治疗溃疡性结肠炎的可控药物递送载体:简要综述。
Saudi Pharm J. 2016 Jul;24(4):458-72. doi: 10.1016/j.jsps.2014.10.001. Epub 2014 Oct 22.
5
Evaluation of in vivo efficacy and toxicity of prednisolone-loaded hydrogel-based drug delivery device.载有泼尼松龙的水凝胶基药物递送装置的体内疗效和毒性评估。
Int J Pharm Investig. 2013 Oct;3(4):225-33. doi: 10.4103/2230-973X.121308.
6
Development of a nanoparticulate formulation of retinoic acid that suppresses Th17 cells and upregulates regulatory T cells.一种抑制辅助性T细胞17并上调调节性T细胞的维甲酸纳米颗粒制剂的研发。
Self Nonself. 2010 Oct;1(4):335-340. doi: 10.4161/self.1.4.13946.
7
Cellulose-based matrix microspheres of prednisolone inclusion complex: preparation and characterization.载prednisolone 包合物的纤维素基基质微球的制备及表征。
AAPS PharmSciTech. 2011 Mar;12(1):388-400. doi: 10.1208/s12249-011-9602-5. Epub 2011 Feb 26.
8
Prednisolone-loaded PLGA microspheres. in vitro characterization and in vivo application in adjuvant-induced arthritis in mice.载泼尼松龙的 PLGA 微球。体外特性和在佐剂诱导关节炎小鼠模型中的体内应用。
AAPS PharmSciTech. 2010 Jun;11(2):859-69. doi: 10.1208/s12249-010-9445-5. Epub 2010 May 19.
9
In vitro and in vivo evaluation of microparticulate drug delivery systems composed of macromolecular prodrugs.由大分子前药组成的微粒药物递送系统的体外和体内评价
Molecules. 2008 Aug 10;13(9):2136-55. doi: 10.3390/molecules13092136.